Evidence-based recommendations on faecal immunochemical tests (OC Sensor, HM-JACKarc, FOB Gold and RIDASCREEN) to guide GP referral for colorectal cancer
Evidence-based recommendations on rapid tests for group A streptococcal infections in people aged 5 and over with a sore throat
Evidence-based recommendations on tests to help assess risk of acute kidney injury for people being considered for critical care admission. The tests are the
Evidence-based recommendations on high-sensitivity troponin tests for the early rule out of NSTEMI (non-ST-segment elevation myocardial infarction)
Evidence-based recommendations on implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke
Evidence-based recommendations on the SepsiTest assay for rapidly identifying bloodstream bacteria and fungi
Evidence-based recommendations on the MiniMed Paradigm Veo and Vibe and G4 PLATINUM CGM sensor-augmented pump therapy systems, which combine continuous glucose
Evidence-based recommendations on PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecsys immunoassay sFlt-1/PlGF ratio, DELFIA
Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.
Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype
Evidence-based recommendations on integrated multiplex polymerase chain tests (xTAG Gastrointestinal Pathogen Panel, FilmArray GI Panel and Faecal Pathogens B
Evidence-based recommendations on using immunohistochemistry or microsatellite instability testing to guide further testing for Lynch syndrome in people with
Evidence-based recommendations on virtual chromoendoscopy (VCE) using NBI, FICE or i-scan to assess colorectal polyps of 5 mm or less during colonoscopy
NICE has assessed the procalcitonin tests (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT
Evidence-based recommendations on the VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative
Evidence-based recommendations on NIOX MINO, NIOX VERO and NObreath for measuring the amount of exhaled nitric oxide (FeNO) in the breath to help diagnose
Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included
In development [GID-DG10041] Expected publication date: 23 February 2022
In development [GID-DG10042] Expected publication date: 13 April 2022
Evidence-based recommendations on the EOS 2D/3D imaging system for producing 2D and 3D images of the skeleton
In development [GID-DG10038] Expected publication date: 06 January 2021
Evidence-based recommendations on point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast. The tests are
In development [GID-DG10029] Expected publication date: 13 January 2021
In development [GID-DG10034] Expected publication date: 17 February 2021
NICE has assessed 3 viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems), to help the NHS decide whether to use these products
Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the
Evidence-based recommendations on 3 electroencephalography (EEG)-based depth of anaesthesia monitors for assessing a patient’s response to anaesthetic drugs
Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery
Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits)
Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic
In development [GID-NG10050] Expected publication date: TBC
In development [GID-NG10140] Expected publication date: 15 December 2021
In development [GID-NG10142] Expected publication date: 09 February 2022
In development [GID-NG10139] Expected publication date: 06 April 2022
In development [GID-NG10121] Expected publication date: 27 September 2021
In development [GID-NG10125] Expected publication date: 10 May 2022
In development [GID-NG10170] Expected publication date: 16 March 2022
This guidance has been updated and replaced by NICE guideline NG47.
This guidance has been updated and replaced by NICE guideline NG151.
In development [GID-HST10004] Expected publication date: TBC
In development [GID-HST10007] Expected publication date: TBC
This guidance has been updated and replaced by NICE diagnostics guidance 40.
In development [GID-DT28] Expected publication date: TBC
Both index tests included in this guidance are no longer commercially available. Therefore the guidance has been withdrawn.
This guideline has been updated and replaced by NICE guideline NG131.
This guidance has been updated and replaced by NICE diagnostics guidance 34.
This guidance has been updated and replaced by NICE diagnostics guidance 32.
In development [GID-DT9] Expected publication date: TBC
In development [GID-DT14] Expected publication date: TBC